Astrana Health, Inc. ASTH
36.37
1.93
5.60%
as of 25 Sep
- Market cap
- $1.7B
- P/E
- 43.6×
Follow ASTH
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
149.21 | 53.93 | 39.55 | 55.92 |
P/S ratio |
0.48 | 0.38 | 0.34 | 0.59 | |
P/FCF ratio |
14.39 | 11.65 | 7.73 | 24.15 | |
P/Operating CF |
140.16 | (421.89) | 17.60 | 69.61 | |
P/B ratio |
1.77 | 1.53 | 1.47 | 2.71 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.68 | 0.57 | 0.50 | 0.73 | |
EV/EBITDA |
19.49 | 14.24 | 12.02 | 16.75 | |
EV/Operating CF |
18.60 | 15.94 | 10.52 | 26.10 | |
EV/FCF |
20.44 | 17.48 | 11.27 | 29.83 | |
Quick Ratio |
1.36 | 1.35 | 1.31 | 1.19 | |
Current Ratio |
1.40 | 1.40 | 1.35 | 1.23 | |
Net Debt/EBITDA |
16.31 | 16.95 | 12.17 | 10.50 | |
Debt/Assets |
46.93% | 46.82% | 43.57% | 41.04% | |
Debt/Equity |
1.33 | 1.31 | 1.26 | 1.11 | |
Asset Turnover |
1.64 | 1.78 | 1.91 | 2.06 | |
Operating CF/Net income |
26.69 | (0.48) | 4.71 | 1.66 | |
Capex/Depreciation |
(0.15) | (0.17) | (0.24) | (0.23) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
6.53% | 6.34% | 6.40% | 5.57% | |
Intangible Assets out of Total Assets |
0.51 | 0.51 | 0.48 | 0.50 | |
Share Based Compensation of Revenue |
0.81% | 1.20% | 1.03% | 1.21% | |
Graham Net Nets |
(0.40) | (0.46) | (0.45) | (0.23) | |
Graham Number |
8.28 | 12.93 | 15.26 | 17.88 | |
Earnings Yield |
0.67% | 1.85% | 2.53% | 1.79% | |
Free Cash Flow Yield |
6.95% | 8.58% | 12.94% | 4.14% | |
Revenue per Share |
19.43 | 19.37 | 19.75 | 19.80 | |
Operating CF per Share |
0.20 | (0.06) | 1.39 | 0.67 | |
Capex per Share |
(0.05) | (0.06) | (0.08) | (0.08) | |
Free Cash Flow per Share |
0.15 | (0.12) | 1.31 | 0.59 | |
Cash per Share |
9.42 | 8.75 | 9.79 | 8.16 | |
Shareholders Equity per Share |
16.03 | 16.16 | 16.69 | 17.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.03 | 16.16 | 16.69 | 17.12 | |
Free Cash Flow |
7.40 | (5.95) | 64.06 | 28.87 | |
Working Capital |
253.70 | 248.04 | 258.73 | 171.52 | |
Capital Expenditures |
(2.55) | (3.06) | (4.00) | (3.88) | |
Net Current Asset Value |
(564.48) | (562.05) | (539.53) | (522.08) | |
EV/EBIT |
32.57 | 23.26 | 20.21 | 28.03 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.04% | 0.63% | 1.50% | 2.03% | |
Price to Operating Income |
22.93 | 15.51 | 13.85 | 22.69 | |
| Other line items | |||||
Average Receivables |
308.62 | 363.73 | 412.03 | 427.24 | |
Average Payables |
152.28 | 151.03 | 163.47 | 182.76 | |
Average Assets |
1,761.28 | 1,786.78 | 1,845.04 | 1,862.22 | |
Average Common Equity |
749.35 | 755.01 | 782.82 | 806.18 |
Columns are period end dates